Brief: Arvinas Enters Into Transaction With Novartis, Including Global License Agreement

Arvinas

11/04/2024 12:08

April 11 (Reuters) - Arvinas Inc  ARVN.O :
    * ARVINAS ENTERS INTO A TRANSACTION WITH NOVARTIS, INCLUDING
A
GLOBAL LICENSE AGREEMENT FOR THE DEVELOPMENT AND
COMMERCIALIZATION OF PROTAC® ANDROGEN RECEPTOR (AR) PROTEIN
DEGRADER ARV-766 FOR THE TREATMENT OF PROSTATE CANCER
    * ARVINAS INC: NOVARTIS TO BE RESPONSIBLE FOR WORLDWIDE
CLINICAL
DEVELOPMENT AND COMMERCIALIZATION OF ARV-766
    * ARVINAS INC: TO RECEIVE A $150 MILLION UPFRONT PAYMENT
    * ARVINAS INC: POTENTIAL UNDER LICENSE AGREEMENT FOR UP TO
$1.01
BILLION IN MILESTONES

Source text for Eikon:  ID:nGNX1ttDvc 
Further company coverage:  ARVN.O 

 ((Reuters.Briefs@thomsonreuters.com;))